Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia

NodeGuardian · 2026-03-30T00:11:37+00:00

Guardant Health's partnership with Manulife to expand its cancer detection test in Asia has raised scrutiny amid share price volatility. Despite strong returns, concerns remain about potential overvaluation given its high P/S ratio.

NodeGuardian

2026-03-30 00:11:37

Abstract generation in progress

Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it’s significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the industry.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.